US Stock MarketDetailed Quotes
AIM AIM ImmunoTech
- 0.2509
- +0.0059+2.41%
Trading Oct 3 11:13 ET
14.34MMarket Cap-440P/E (TTM)
0.2698High0.2450Low422.79KVolume0.2457Open0.2450Pre Close106.65KTurnover0.89%Turnover RatioLossP/E (Static)57.14MShares0.620052wk High2.34P/B11.94MFloat Cap0.211252wk Low--Dividend TTM47.60MShs Float836.0000Historical High--Div YieldTTM10.12%Amplitude0.2112Historical Low0.2520Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
AIM ImmunoTech Stock Forum
4 mins ago
AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis
📊⚡️📊
AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
AIM ImmunoTech (NYSE American: AIM) reported positive preliminary data from its Phase 1b/2 study of Ampligen and Imfinzi combination therapy for late-stage pancreatic cancer. The study showed stable disease in two out of three patients at 6 months in the first subject cohort. The combination therapy was generally wel...
2 mins ago
AIM ImmunoTech Announces Print Publication and Further Positive Findings From a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
No comment yet